Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 over exp TP53 wild-type |
Therapy | KRT-232 |
Indication/Tumor Type | ovarian clear cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 over exp TP53 wild-type | ovarian clear cell carcinoma | predicted - sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment sensitized ovarian clear cell carcinoma cell lines harboring wild-type TP53 and MDM2 overexpression to T-cell mediated killing when co-cultured with T-cells, demonstrating decreased cell viability (PMID: 32655895). | 32655895 |
PubMed Id | Reference Title | Details |
---|---|---|
(32655895) | AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. | Full reference... |